Epidemiology of HF in SSA
Although there have been no population-based epidemiological studies of HF in Africa, there have been a number of hospital-based studies that give important insights into the incidence and prevalence of HF in SSA. In contrast to other parts of the world, non-ischaemic aetiologies are predominant, with hypertension, rheumatic heart disease (RHD) and cardiomyopathy accounting for two-thirds of cases of HF in hospitalised patients in the region. [1, 5] 
Classification of HF
Patients with HF can be divided into two categories: HF with reduced ejection fraction (HF-REF), and HF with preserved ejection fraction (HF-PEF) (Fig. 1) . Although there is poor correlation between symptom severity and left ventricular ejection fraction (LVEF), the LVEF carries independent prognostic significance and is considered abnormal when <50%. [2] The diagnosis of HF-PEF is more difficult, and although LVEF is normal or only mildly reduced in this condition, relevant structural heart disease and/or diastolic dysfunction should be present to make this diagnosis. Importantly, HF-PEF is a diagnosis of exclusion where other non-cardiac causes for patients' symptoms must be considered and discounted. [2] Patients with HF-PEF are older, more often female and obese, and more likely to have hypertension and atrial fibrillation, compared to those with HF-REF, and their prognosis appears to be better overall. [6] Aetiology of HF in SSA HF is a final common pathway for a number of conditions affecting the heart, and it is useful to classify the aetiology according to the following diseases: (i) hypertension; (ii) primary myocardial disease that includes cardiomyopathies and myocarditis; (iii) valvular heart disease; (iv) ischaemic heart disease; (v) congenital heart disease; (vi) pericardial disease; and (vii) pulmonary hypertension (PH) ( Table 1) . It is important to consider alternative causes for fluid retention (e.g. renal or liver disease) and pulmonary oedema (e.g. neurogenic) in the context of a structurally normal heart. January 2016, Vol. 106, No. 1 underfilling, leading to renal sodium and water retention via activation of the above-mentioned neuro-endocrine systems, in an attempt to restore arterial circulatory integrity (Fig. 2) . [7] 
Clinical presentation
The history is key in making the diagnosis of HF, grading symptom severity, and establishing not only the underlying cause but also identifying factors that may have precipitated decompensation ( Table 2 ). The typical symptoms of HF are breathlessness, orthopnoea, paroxysmal 
NYHA Class IV (severe symptoms)
Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort is increased nocturnal dyspnoea, reduced effort tolerance, fatigue, and ankle swelling. The New York Heart Association (NYHA) functional class allows a grading of symptom severity in a standardised manner (Fig. 1) . [2] Exploring past medical history, environmental exposures and family history may assist in deciphering a possible aetiology.
The physical examination findings may differ, depending on the underlying aetiology, but pedal oedema, raised jugular venous pressure, a tender hepatomegaly and basal crackles indicate congestive HF. Additional features that can be found on examination are listed in Table 3 .
Diagnostic tests in suspected HF
The baseline investigations recommended in clinical assessment of HF are outlined in Table 4 . The electrocardiogram (ECG) and echocardiogram are the most useful investigations, as they confirm the presence of underlying structural heart disease. The likelihood of a normal ECG in a patient presenting with HF is low, making it an extremely helpful screening tool. [2] It is recommended that all patients with a new diagnosis of HF undergo echocardiographic evaluation as it confirms the type of structural heart disease present and provides information on cardiac function. [2] Understanding the aetiology of HF is vital when determining definitive management strategies and prognosis. The pursuit of a correctable cause and identification of reversible factors are central to improving outcomes in these patients. Patients with unexplained HF, particularly those who are not improving on standard therapy, should be referred for specialist review where advanced investigations can be done to establish a diagnosis (Table 4) .
Specific aetiologies of HF Hypertension
Hypertension has been reported as the dominant cause of HF in Africa, responsible for up to 46% of cases of HF in hospitalised patients. [4, 5, 8] Young hypertensive patients should be investigated for secondary causes of hypertension (Table 1) . Standard anti-failure therapy and blood pressure control are the mainstays of therapy. PH with unclear and/ or multifactorial mechanism HCM = hypertrophic cardiomyopathy; DCM = dilated cardiomyopathy; ARVC = arrhythmogenic right ventricular cardiomyopathy; PH = pulmonary hypertension; CHD = congenital heart disease; RCM = restrictive cardiomyopathy.
Cardiomyopathy
Cardiomyopathy accounts for 20 -30% of heart failure in Africans. [1] Most commonly, patients who present with HF have a dilated phenotype, and potentially treatable causes for dilated cardiomyopathy should routinely be excluded (Table 1) . Importantly, patients with other forms of cardiomyopathy (hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), restrictive cardiomyopathy (RCM), and left ventricular non-compaction) presenting with HF should be referred for specialist review, as the management of these conditions is complex and multi disciplinary. [9] Myocarditis should be considered in patients who present with cardiac symptoms and elevated cardiac biomarkers (tropo nin T or I), ECG abnormalities and/or evidence of functional impairment on echocardiogram, where acute coronary syndrome has been excluded. [10, 11] Forty-four percent of HIVassociated cardiomyopathy cases have evidence of myocarditis on endo myocardial biopsy, either as a result of HIV or secondary to opportunistic infections, [12] justifying antiretroviral therapy in these patients.
Valvular heart disease
In contrast to Western populations, where valvular heart disease is mainly degenerative, in SSA valvular heart disease is predominantly caused by rheumatic fever and infective endocarditis. Despite a reduction in RHD as a cause of HF in SSA in recent years, it remains endemic on our continent. [13] The mainstay of treatment for patients with symptomatic valvular heart disease is surgery, complemented by anti-failure therapy and secondary prevention of rheumatic fever with penicillin in RHD. All patients should be referred for evaluation for surgery.
Ischaemic heart disease
Ischaemic heart disease (IHD) is an uncommon cause of HF in SSA, accounting for only 7.7 -9% of cases. [3, 4, 8] Although IHD is considered uncommon among black Africans, there has been a notable rise in risk factors for atherosclerotic vascular disease in both urban and rural communities over the last few decades. [14] Patients presenting with ischaemic left ventricular dysfunction require rigorous risk factor management in addition to conventional HF therapy. Patients with suspected coronary artery disease with ongoing symptoms of angina should be referred to a cardiologist for consideration for revascularisation therapy. [2, 15] 
Congenital heart disease
Although the prevalence of congenital heart disease (CHD) in SSA is considered to be the lowest in the world, it is likely that this [16] CHD is riddled with complexity and requires management by experienced clinicians. [2] Pericardial disease Pericardial disease has a broad aetiology, but tuberculous pericarditis is the commonest cause of pericardial effusion, cardiac tampo nade, and constrictive pericarditis in SSA, and carries a high mortality rate despite antituberculosis therapy, pericardiocentesis and pericardectomy. [17] Pulmonary hypertension PH is a debilitating progressive disease that leads to right HF, and although little is currently known about the epidemiology of PH in Africa, the reported incidence appears to be higher than in developed countries. The Pan African Pulmonary Hypertension Cohort study hopes to address the paucity of our knowledge. Importantly, many risk factors associated with PH are endemic in SSA (Table 1) . [18] PH (not associated with left heart pathology) requires investigation in the absence of significant pulmonary disease.
Management of HF
Although a significant portion of HF management falls within the realm of the general practitioner and general physician, it is important to be able to recognise which patients require specialist referral, particularly where there is diagnostic uncertainty and/or failure to improve, or deterioration, on anti-failure therapy.
The goals of treatment in patients with established HF are to: (i) relieve symptoms with the aim to improve quality of life and functional capacity; (ii) prevent recur rent hospitalisations; and (iii) improve survival. In SSA these goals are achieved predominantly through patient education and medical therapy. Despite resource restraints, there is a role for advanced medical, device and surgical interventions, including orthotopic heart transplantation, for HF in SSA. It is important for clinicians to familiarise themselves with the indica tions and the availability of services.
[2]
Patient education
It is the attending clinicians' responsibility to inform patients about their condition. Important aspects to consider are listed in Table 5 .
Optimising medical therapy
Medical therapy consists of two components: (i) disease-modifying drugs consisting of three neurohormonal antagonists (angiotensinconverting enzyme (ACE) inhibitors (or angiotensin receptor blockers), beta-blockers, and mineralocorticoid receptor antagonists) that are fundamental in modifying the course of disease and improving survival;
and (ii) symptomatic therapies, such as diuretics and digoxin, that relieve congestion, reduce hospitalisation and improve quality of life. Fig. 3 illustrates an approach for the medical management of HF. The first step is to manage and alleviate congestion. Diseasemodifying drugs should be introduced at recommended starting doses and titrated up to maximum tolerated doses over a number of weeks (Table 6) . [2] Digoxin has been shown to relieve symptoms and reduce hospitalisations, [19] but is associated with an increase in mortality in HF patients. [20] Current guidelines recommend low-dose digoxin in selected patients who remain symptomatic despite optimal ACE inhibitor and betablocker therapy. Hypokalaemia and renal failure predispose patients to digoxin toxicity, and its use is contraindicated in these circumstances. [21] The prognosis of acute decompensated HF remains poor, with greater severity of congestion being associated with worse outcomes. Acute decompensated HF is associated with an in-hospital mortality rate of up to 8.3% in Africa. [8] Fluid retention and congestion are responsible for 90% of HF hospital admissions, and even with diuretic therapy approximately 40% of patients are discharged with unresolved congestion. [22] The mainstay therapy for the treatment of congestion is loop diuretics. Diuretic resistance is the failure to adequately control salt and water retention despite appropriate dose escalation of loop diuretics. The doseresponse curve for loop diuretics shifts in HF, resulting in the need for increased doses of the drug to achieve a therapeutic effect; thus inadequate dosing must be differentiated from diuretic resistance. Infrequent dosing can result in rebound salt and water retention, which can be addressed by increasing the frequency of dosing or changing to a continuous intravenous infusion.
Strategies for overcoming diuretic resistance include the addition of thiazide diuretics and/or spironolactone. Importantly, diuretic combinations can result in severe volume depletion and electrolyte disturbances, and should only be used in circumstances where volume status and electrolytes can be monitored. RAAS activation plays an important role in sodium and water retention by increasing distal sodium reabsorption in the kidney. Introducing ACE inhibitors is crucial in managing congestion. The challenge is maintaining adequate arterial blood pressure, as low blood pressure drives plasma renin activity and further activation of RAAS (Fig. 4) . [22] Advanced medical, device and surgical interventions Heart rate reduction improves clinical out comes in HF. Beta-blocker dosage should be titrated to maintain a resting heart rate <75 beats/minute. In instances where patients are unable to tolerate increased doses of beta-blockers, ivabradine can be considered. Ivabradine inhi bits the I f channel in the sinus node and can be used to slow the heart rate in patients in sinus rhythm. [2] Indications for device and surgical interventions are listed in Table 7 . [2, 23] 
Conclusion
HF is a common condition that is caused by a diverse group of aetiologies, representing unique disease entities that require different management strategies. It is for this reason What heart failure is and why symptoms occur The underlying cause of their heart failure Prognosis The treatment options available to them
Patients must be educated about: Medications, specifically the role of each drug used to treat heart failure Fluid retention and how to manage it (i.e. how to restrict fluids, monitor weight and adjust diuretic therapy accordingly) Remembering the names, doses and frequency of medication they are on or bringing the drugs to hospital with them (Table 6) ACE inhibitors (or ARB) and beta-blockers can be introduced one at a time, or simultaneously, at low doses. Titrate to maximum tolerated doses over a number of weeks + Mineralocorticoid receptor antagonist
Monitor renal function and potassium Consider the following:
• Has the underlying aetiology of the heart been adequately addressed?
• Is the patient still congested? Ask about uid intake • Is the patient compliant on medication? Ask about side-e ects • Is the patient on optimal (tolerated) doses of ACE inhibitors, beta-blockers and mineralocorticoid antagonists?
• Are there any exacerbating factors or an alternative pathology causing these symptoms? (Table 2) e.g. anaemia, new arrhythmia, ischaemia, infection, thyroid disease, pregnancy, renal impairment, autoimmune conditions, lung disease, depression, diabetes • Consider low-dose digoxin if renal function is normal
ASSESSMENT BY CARDIOLOGIST CONSIDERATION FOR DEVICE AND/OR SURGICAL INTERVENTION, INCLUDING TRANSPLANTATION (Table 7)
Sinus rhythm and heart rate ≥75 beats/minute → consider ivabradine Refractory heart failure, QRS duration >120 ms and LVEF ≤35% → consider cardiac resynchronisation therapy that diagnostic certainty is as important as treating the clinical syndrome of HF. Effective diuresis and complete resolution of congestion is key in improving symptoms and functional capacity, reducing the need for recurrent hospitalisation, increasing the probability of establishing patients on good doses of disease-modifying drugs, and ultimately improving outcomes. Heart transplantation End-stage heart failure with severe symptoms, a poor prognosis, and no remaining alternative treatment option Motivated, well-informed, and emotionally stable Capable of complying with the intense treatment required postoperatively Contraindications to transplantation Active infection, significant comorbidities (e.g. severe peripheral vascular disease, cerebrovascular disease, renal failure, liver disease, systemic multiorgan disease), recurrent thromboembolism, unhealed peptic ulcer, current alcohol or drug abuse, emotional/psychiatric instability, cancer within the previous 5 years High, fixed pulmonary vascular resistance (>4 -5 Wood units and mean transpulmonary gradient >5 mmHg) ICD = implantable cardioverter-defibrillator; CRT = cardiac resynchronisation therapy; SCD = sudden cardiac death; HCM = hypertrophic cardiomyopathy.
